vs

Side-by-side financial comparison of BICYCLE THERAPEUTICS PLC (BCYC) and ESCALADE INC (ESCA). Click either name above to swap in a different company.

ESCALADE INC is the larger business by last-quarter revenue ($62.6M vs $48.0M, roughly 1.3× BICYCLE THERAPEUTICS PLC). ESCALADE INC runs the higher net margin — 5.9% vs -42.0%, a 47.9% gap on every dollar of revenue. On growth, BICYCLE THERAPEUTICS PLC posted the faster year-over-year revenue change (1193.3% vs -2.2%). ESCALADE INC produced more free cash flow last quarter ($13.7M vs $-19.9M). Over the past eight quarters, BICYCLE THERAPEUTICS PLC's revenue compounded faster (56.7% CAGR vs 4.5%).

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical firm developing innovative bicyclic peptide therapies for unmet medical needs. Its core pipeline covers oncology, rare diseases, and immunological disorders, with operations in Europe and North America, and partnerships with global pharma leaders to advance drug candidates to market.

Escalade Inc is a global sporting goods manufacturer and distributor that offers basketball systems, archery equipment, table tennis gear, game tables, and outdoor recreation accessories. It operates primarily across North America, Europe, and Asia Pacific, serving consumer retail, commercial fitness, and specialty sports segments.

BCYC vs ESCA — Head-to-Head

Bigger by revenue
ESCA
ESCA
1.3× larger
ESCA
$62.6M
$48.0M
BCYC
Growing faster (revenue YoY)
BCYC
BCYC
+1195.4% gap
BCYC
1193.3%
-2.2%
ESCA
Higher net margin
ESCA
ESCA
47.9% more per $
ESCA
5.9%
-42.0%
BCYC
More free cash flow
ESCA
ESCA
$33.6M more FCF
ESCA
$13.7M
$-19.9M
BCYC
Faster 2-yr revenue CAGR
BCYC
BCYC
Annualised
BCYC
56.7%
4.5%
ESCA

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BCYC
BCYC
ESCA
ESCA
Revenue
$48.0M
$62.6M
Net Profit
$-20.2M
$3.7M
Gross Margin
27.7%
Operating Margin
-51.5%
8.2%
Net Margin
-42.0%
5.9%
Revenue YoY
1193.3%
-2.2%
Net Profit YoY
61.1%
37.1%
EPS (diluted)
$-0.29
$0.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BCYC
BCYC
ESCA
ESCA
Q4 25
$48.0M
$62.6M
Q3 25
$11.7M
$67.8M
Q2 25
$2.9M
$54.3M
Q1 25
$10.0M
$55.5M
Q4 24
$3.7M
$63.9M
Q3 24
$2.7M
$67.7M
Q2 24
$9.4M
$62.5M
Q1 24
$19.5M
$57.3M
Net Profit
BCYC
BCYC
ESCA
ESCA
Q4 25
$-20.2M
$3.7M
Q3 25
$-59.1M
$5.6M
Q2 25
$-79.0M
$1.8M
Q1 25
$-60.8M
$2.6M
Q4 24
$2.7M
Q3 24
$-50.8M
$5.7M
Q2 24
$-39.8M
$2.8M
Q1 24
$-26.6M
$1.8M
Gross Margin
BCYC
BCYC
ESCA
ESCA
Q4 25
27.7%
Q3 25
28.1%
Q2 25
24.7%
Q1 25
26.7%
Q4 24
24.9%
Q3 24
24.8%
Q2 24
24.2%
Q1 24
25.0%
Operating Margin
BCYC
BCYC
ESCA
ESCA
Q4 25
-51.5%
8.2%
Q3 25
-558.6%
10.8%
Q2 25
-2965.8%
4.8%
Q1 25
-703.7%
6.6%
Q4 24
7.1%
Q3 24
-2385.9%
11.8%
Q2 24
-498.3%
7.1%
Q1 24
-162.4%
5.3%
Net Margin
BCYC
BCYC
ESCA
ESCA
Q4 25
-42.0%
5.9%
Q3 25
-503.7%
8.2%
Q2 25
-2703.8%
3.4%
Q1 25
-608.9%
4.7%
Q4 24
4.2%
Q3 24
-1898.4%
8.4%
Q2 24
-425.3%
4.5%
Q1 24
-136.0%
3.1%
EPS (diluted)
BCYC
BCYC
ESCA
ESCA
Q4 25
$-0.29
$0.27
Q3 25
$-0.85
$0.40
Q2 25
$-1.14
$0.13
Q1 25
$-0.88
$0.19
Q4 24
$0.20
Q3 24
$-0.74
$0.40
Q2 24
$-0.77
$0.20
Q1 24
$-0.62
$0.13

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BCYC
BCYC
ESCA
ESCA
Cash + ST InvestmentsLiquidity on hand
$628.1M
Total DebtLower is stronger
$18.5M
Stockholders' EquityBook value
$610.0M
$173.2M
Total Assets
$717.6M
$222.1M
Debt / EquityLower = less leverage
0.11×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BCYC
BCYC
ESCA
ESCA
Q4 25
$628.1M
Q3 25
$648.3M
Q2 25
$721.5M
Q1 25
$793.0M
Q4 24
$879.5M
Q3 24
$890.9M
Q2 24
$961.4M
Q1 24
$457.0M
Total Debt
BCYC
BCYC
ESCA
ESCA
Q4 25
$18.5M
Q3 25
Q2 25
Q1 25
Q4 24
$25.6M
Q3 24
Q2 24
$30.9M
Q1 24
$30.8M
Stockholders' Equity
BCYC
BCYC
ESCA
ESCA
Q4 25
$610.0M
$173.2M
Q3 25
$618.5M
$172.3M
Q2 25
$668.9M
$168.3M
Q1 25
$740.3M
$168.8M
Q4 24
$793.1M
$169.0M
Q3 24
$831.0M
$170.1M
Q2 24
$873.8M
$166.0M
Q1 24
$356.0M
$164.7M
Total Assets
BCYC
BCYC
ESCA
ESCA
Q4 25
$717.6M
$222.1M
Q3 25
$764.0M
$232.5M
Q2 25
$832.2M
$218.3M
Q1 25
$883.9M
$222.1M
Q4 24
$956.9M
$226.3M
Q3 24
$996.7M
$244.9M
Q2 24
$1.1B
$243.1M
Q1 24
$547.1M
$256.3M
Debt / Equity
BCYC
BCYC
ESCA
ESCA
Q4 25
0.11×
Q3 25
Q2 25
Q1 25
Q4 24
0.15×
Q3 24
Q2 24
0.04×
Q1 24
0.09×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BCYC
BCYC
ESCA
ESCA
Operating Cash FlowLast quarter
$-19.3M
$14.9M
Free Cash FlowOCF − Capex
$-19.9M
$13.7M
FCF MarginFCF / Revenue
-41.5%
21.8%
Capex IntensityCapex / Revenue
1.2%
2.0%
Cash ConversionOCF / Net Profit
4.02×
TTM Free Cash FlowTrailing 4 quarters
$-252.0M
$28.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BCYC
BCYC
ESCA
ESCA
Q4 25
$-19.3M
$14.9M
Q3 25
$-71.2M
$-965.0K
Q2 25
$-72.8M
$13.3M
Q1 25
$-86.4M
$3.8M
Q4 24
$-164.7M
$12.3M
Q3 24
$-39.8M
$10.5M
Q2 24
$-44.6M
$13.3M
Q1 24
$-70.9M
$7.0K
Free Cash Flow
BCYC
BCYC
ESCA
ESCA
Q4 25
$-19.9M
$13.7M
Q3 25
$-71.8M
$-1.3M
Q2 25
$-73.3M
$12.9M
Q1 25
$-87.0M
$3.2M
Q4 24
$-166.0M
$11.7M
Q3 24
$-40.3M
$10.2M
Q2 24
$-45.0M
$12.5M
Q1 24
$-70.9M
$-350.0K
FCF Margin
BCYC
BCYC
ESCA
ESCA
Q4 25
-41.5%
21.8%
Q3 25
-612.3%
-1.9%
Q2 25
-2509.7%
23.7%
Q1 25
-871.7%
5.9%
Q4 24
-4475.7%
18.4%
Q3 24
-1504.7%
15.0%
Q2 24
-481.2%
20.0%
Q1 24
-362.9%
-0.6%
Capex Intensity
BCYC
BCYC
ESCA
ESCA
Q4 25
1.2%
2.0%
Q3 25
5.7%
0.4%
Q2 25
17.1%
0.8%
Q1 25
6.1%
1.0%
Q4 24
33.3%
0.9%
Q3 24
16.3%
0.5%
Q2 24
4.5%
1.3%
Q1 24
0.1%
0.6%
Cash Conversion
BCYC
BCYC
ESCA
ESCA
Q4 25
4.02×
Q3 25
-0.17×
Q2 25
7.28×
Q1 25
1.45×
Q4 24
4.55×
Q3 24
1.85×
Q2 24
4.67×
Q1 24
0.00×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons